Albemarle's Q4 2007 fine chemicals sales decreases 20% to $131.1m, primarily due to reduced revenue from clear brines volumes and the absence of revenue from manufacturing intermediates for Tamiflu in 2006. However, full year fine chemicals income rose 40% to $86.9m.
Forbes
Tuesday 29 January 2008
Up and down for Albemarle
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment